sharetrader
Page 3 of 30 FirstFirst 123456713 ... LastLast
Results 21 to 30 of 296
  1. #21
    Member jim9358's Avatar
    Join Date
    Jul 2016
    Location
    Dunedin
    Posts
    57

    Default

    Someone is manipulating jumping it to 27 when offers at 23, 24, 25! I'm not offering anymore!

  2. #22
    Member jim9358's Avatar
    Join Date
    Jul 2016
    Location
    Dunedin
    Posts
    57

    Default

    Finally got my offer: Really pleased to be into this (at right price) even if it takes a while to become a serious stock. Now I'm a holder intend sharing biz ideas with them direct! (but as mentioned, think they have someone good on-board in the marketing game) Next sales reports will be the tell-all. If what I'm picking this stock could go amongst the best;-)

  3. #23
    Advanced Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    1,701

    Default

    Good news for Promisia, still a penny stock but maybe not such a 'penny dreadful' now. Another loss but nearly a million in sales, and apart from NZ target markets are barely touched yet. It was mentioned at the recent ASM that sales revenue in NZ exceeds the advertising spend. I see a lot of TV and internet advertising.

    Sounds like Arthrem for dogs is well on the way, with the palatibility issue apparently sorted. Could be a lucrative global market as it is a natural product, and cheaper than a visit to the vet plus prescription.

    And a hint of another product with a clinical trial begun.

  4. #24
    Member jim9358's Avatar
    Join Date
    Jul 2016
    Location
    Dunedin
    Posts
    57

    Default

    Quote Originally Posted by artemis View Post
    Good news for Promisia, still a penny stock but maybe not such a 'penny dreadful' now. Another loss but nearly a million in sales, and apart from NZ target markets are barely touched yet. It was mentioned at the recent ASM that sales revenue in NZ exceeds the advertising spend. I see a lot of TV and internet advertising.

    Sounds like Arthrem for dogs is well on the way, with the palatibility issue apparently sorted. Could be a lucrative global market as it is a natural product, and cheaper than a visit to the vet plus prescription.

    And a hint of another product with a clinical trial begun.
    someone just made me 28% better off today LOL. Already thinking to increase my holding. Cripes, if they go to a dollar next couple years I could retire! ...ride my MT-bike more! ;-) A million sales is poor really: It's the turn-over barely good enough for a one-man-band. We'll know they're worth something when they get to TEN mill in sales which they need to get to pronto to stretch out time that they'll get "run over" by competitors! IMHO.
    Last edited by jim9358; 30-08-2016 at 12:07 PM.

  5. #25
    Outside thinking.
    Join Date
    Jan 2013
    Posts
    2,563

    Default

    Quote Originally Posted by jim9358 View Post
    someone just made me 28% better off today LOL. Already thinking to increase my holding. Cripes, if they go to a dollar next couple years I could retire! ...ride my MT-bike more! ;-) A million sales is poor really: It's the turn-over barely good enough for a one-man-band. We'll know they're worth something when they get to TEN mill in sales which they need to get to pronto to stretch out time that they'll get "run over" by competitors! IMHO.
    Well done holders.....I sense the beginnings of another BLT here!

  6. #26
    Member jim9358's Avatar
    Join Date
    Jul 2016
    Location
    Dunedin
    Posts
    57

    Default

    Quote Originally Posted by Left field View Post
    Well done holders.....I sense the beginnings of another BLT here!
    sure hope not! (tongue-n-cheek right?)

  7. #27
    Member jim9358's Avatar
    Join Date
    Jul 2016
    Location
    Dunedin
    Posts
    57

    Default

    QUOTE:
    "as at 08:30:27, Tuesday 30 August, 2016 (NZT)HALFYR: PIL: 600% sales increase for Promisia
    PIL
    30/08/2016 08:30
    HALFYR
    PRICE SENSITIVE
    REL: 0830 HRS Promisia Integrative Limited

    HALFYR: PIL: 600% sales increase for Promisia

    Report of the Chairman and Chief Executive

    The Chairman and Chief Executive are pleased to report the Half Year Report
    for Promisia Integrative Limited and its subsidiaries ("the Group") for the
    six month period ended 30 June 2016.

    Sales
    We are pleased to report healthy sales of $994,098 for Arthrem which is
    $850,000, or 600%, more than the sales of $142,000 for the same period in
    2015.
    According to IRI-AZTEC scan pharmacy data, Arthrem is the fasting growing
    brand and product, in dollar terms, for 2016. It also ranks 13th among
    brands in dollar terms in pharmacy for New Zealand.

    Australia
    The company is making good progress towards the launch of Arthrem in
    Australia. Arthrem is now manufactured in a Therapeutic Goods of Australia
    (TGA) compliant facility with Good Manufacturing Practice certification.
    This is an important step, and a prerequisite, to becoming a listed
    complementary medicine in Australia. The listing will allow Arthrem to make
    stronger evidence-based therapeutic claims in its advertising. Current
    legislation prevents these claims being made in New Zealand.

    United States of America
    Sales in the US continue to grow. Cash spend in the US is being managed
    carefully by testing different digital marketing models and using real time
    measurement of their effectiveness.

    Arthritis supplement for dogs
    The major challenge for developing an arthritis supplement product for dogs
    using the Group's unique plant extract has been masking the distinctive
    pungent smell and bitter taste. Unlike humans, who can swallow a capsule
    whole, dogs will smell and chew capsules. Therefore a soft gel capsule is
    not an option.

    The company's Principal Scientist, Dr Sheena Hunt, has developed a
    formulation that masks both the smell and taste of the extract, and is
    palatable to dogs. Manufacturing trials are underway.

    Financial Results
    The $354,000 loss for the Group for the half year, compared to $575,000 for
    2015 same period, is slightly below what was expected due to the delayed
    expenditure for the launch of Arthrem in Australia and the completion of
    development and launch of the arthritis supplement for dogs. Much of this
    budgeted expenditure will be incurred in the second half of the year. The
    loss includes exchange rate movements, interest expenses, amortisation of the
    company's automated marketing website and 50% of known non-cash charges such
    as the share option costs.

    Research
    The focus of the research programme for the first half of the year has been
    the development of a palatable formulation for dogs. The company is also
    researching other possible therapeutic applications for its extract. A
    clinical trial has just started for another product.

    Outlook
    Promisia will continue to promote Arthrem aggressively in the New Zealand
    market. The company is confident that it will exceed its 2016 objective of
    capturing at least 3% of the potential New Zealand 305,000 person
    osteoarthritis market before the end of the year.

    Other priorities for the second half of the year include:
    o Listing Arthrem as a complementary medicine in Australia
    o Preparation for the launch of Arthrem in Australia in early 2017
    o Completion of development and testing of the supplement for dogs
    o Preparation of a product launch and marketing campaign for a dog arthritis
    treatment in New Zealand and Australia
    o Ongoing refinement of the marketing strategy in the US

    On behalf of the directors and management we thank shareholders for their
    continued support for the company.
    End CA:00288096 For:PIL Type:HALFYR Time:2016-08-30 08:30:27"

  8. #28
    Advanced Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    1,701

    Default

    Quote Originally Posted by Left field View Post
    Well done holders.....I sense the beginnings of another BLT here!
    They are both science / evidence based. So a lot of dosh up front before revenue flows.

    Both companies will need a steadily increasing number of repeat customers if they are not to spend too much on attracting new customers.

  9. #29
    Member
    Join Date
    Jun 2012
    Posts
    441

    Default

    Quote Originally Posted by artemis View Post
    They are both science / evidence based. So a lot of dosh up front before revenue flows.

    Both companies will need a steadily increasing number of repeat customers if they are not to spend too much on attracting new customers.
    Agree to a degree. My casual observation is that PIL are somewhat more conservative and measured in their news than BLT who are keen on at least monthly "news of the day" releases. Both approaches are ok I guess.

  10. #30
    Member jim9358's Avatar
    Join Date
    Jul 2016
    Location
    Dunedin
    Posts
    57

    Default

    Quote from above: "...3% of the potential New Zealand 305,000 person osteoarthritis market before the end of the year."

    Think i'll just "put this away in the draw" until end of year and they post improved sales.
    In the meantime have banged my small holding to a sell at 5c flat. Guess I'll know there's positive action if someone kindly more than doubles my money!


Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •